East Midlands Breathomics Pathology Node (EMBER)

东米德兰兹呼吸组学病理学节点 (EMBER)

• 批准号: MR/N005880/1
• 负责人: Christopher Brightling
• 金额: $ 314.53万
• 依托单位: University of Leicester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FN005880%2F1
• 关键词: East; Midlands; Breathomics; Pathology; Node

Our vision is to establish the East Midlands Breathomics Pathology Node (EMBER) as a centre-of-excellence to ensure the development of novel breath analysis tests to help understand disease processes and clinical decision making. This will help develop new ways to improve the way we can chose the right treatment for the right patient. Measuring breath is familar to us all in the setting of the breathalyser to detect alcohol levels, but perhaps less well known is that exhaled breath contains lots of substances known as volatile organic compounds (VOCs) derived from the lung itself and from more distant organs. Recent advances in technology allow the pattern and quantity of these VOCs to be measured rapidly in patients in hospital, the doctors clinic and potentially at home. The patterns of these substances varies between diseases and can distinguish between different types of the same condition. The range of clinical conditions for which breath tests could be useful is very large. EMBER will intially focus upon respiratory infections, lung cancer, chronic respiratory disease such as asthma and chronic obstructive pulmonary disease, and cardiovascular disorders such as heart failure. The main barrier to advancing breath analysis as a routine test is that its development requires bringing together a large multi-disciplinary team of scientists and clinicans that are experts in breath analysis to work with the NHS, industry and patients to make these ideas a reality. The East Midlands has a unique and congruent group of clinical and analytical researchers drawn from the University of Leicester (UoL), the University Hospitals of Leicester NHS Trust (UHL) and Loughborough University (LU) with strengths in clinical research, analytical chemistry, data management and mathematical analysis of complex data. EMBER will focus these combined strengths, and co-ordinates existing collaborations with industry partners to create a nationally-leading centre in breath analysis with the critical mass to establish world-class delivery of new technology to the clinic, and training today's and the future scientists and health care professionals. EMBER will deliver near-patient and remote sensing technologies to analyse breath. We shall rigorously test these technologies in different diseases and in different health care settings such as acute hospitals, secondary and primary care and in the home. We shall include vulnerable patient groups such as the elderly with complicated multiple diseases and children in whom blood tests are more challenging. EMBER will ensure the usefulness of these tests so that their application brings economic and health benefits by helping to make the right decisions in choosing the right treatment for patients.

我们的愿景是建立东米德兰兹呼吸组学病理学节点（EMBER）作为卓越中心，以确保开发新的呼吸分析测试，以帮助了解疾病过程和临床决策。这将有助于开发新的方法来改善我们为正确的患者选择正确治疗的方式。测量呼吸是我们所有人都熟悉的呼吸测醉器的设置来检测酒精水平，但也许不太为人所知的是，呼出的气体含有大量的物质，称为挥发性有机化合物（VOC），来自肺部本身和更远的器官。技术的最新进展使这些VOC的模式和数量能够在医院，医生诊所和家庭中快速测量。这些物质的模式因疾病而异，并且可以区分相同病症的不同类型。呼吸测试可能有用的临床条件的范围非常大。EMBER将首先关注呼吸道感染、肺癌、慢性呼吸道疾病（如哮喘和慢性阻塞性肺病）和心血管疾病（如心力衰竭）。推进呼吸分析作为常规测试的主要障碍是，它的发展需要汇集一个由呼吸分析专家组成的大型多学科科学家和临床医生团队，与NHS，行业和患者合作，使这些想法成为现实。东米德兰兹大学拥有一支独特而一致的临床和分析研究人员队伍，他们来自莱斯特大学（UoL），莱斯特NHS信托大学医院（UHL）和拉夫堡大学（LU），在临床研究，分析化学，数据管理和复杂数据的数学分析方面具有优势。EMBER将专注于这些综合优势，并协调与行业合作伙伴的现有合作，以创建一个全国领先的呼吸分析中心，其关键质量是建立世界一流的临床新技术交付，并培训当今和未来的科学家和医疗保健专业人员。EMBER将提供近距离和遥感技术来分析呼吸。我们将在不同的疾病和不同的卫生保健环境中，如急症医院、二级和初级保健以及家庭中，严格测试这些技术。我们将纳入弱势患者群体，例如患有复杂多种疾病的老年人和血液测试更具挑战性的儿童。EMBER将确保这些测试的有用性，以便它们的应用通过帮助做出正确的决定来为患者选择正确的治疗方法，从而带来经济和健康效益。

项目成果

Automating and Extending Comprehensive Two-Dimensional Gas Chromatography Data Processing by Interfacing Open-Source and Commercial Software.

• DOI: 10.1021/acs.analchem.0c02844
• 发表时间: 2020-10-20
• 期刊: Analytical chemistry
• 影响因子: 7.4
• 作者: Wilde MJ;Zhao B;Cordell RL;Ibrahim W;Singapuri A;Greening NJ;Brightling CE;Siddiqui S;Monks PS;Free RC
• 通讯作者: Free RC

Visualization of exhaled breath metabolites reveals distinct diagnostic signatures for acute cardiorespiratory breathlessness.

• DOI: 10.1126/scitranslmed.abl5849
• 发表时间: 2022-11-16
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Ibrahim W;Wilde MJ;Cordell RL;Richardson M;Salman D;Free RC;Zhao B;Singapuri A;Hargadon B;Gaillard EA;Suzuki T;Ng LL;Coats T;Thomas P;Monks PS;Brightling CE;Greening NJ;Siddiqui S;EMBER Consortium;Munton R;Le Quesne J;Goodall AH;Pandya HC;Reynolds JC;Clokie MRJ;Samani NJ;Barer MR;Shaw JA
• 通讯作者: Shaw JA

Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases.

• DOI: 10.1136/thoraxjnl-2020-215667
• 发表时间: 2021-05
• 期刊: Thorax
• 影响因子: 10
• 作者: Ibrahim W;Carr L;Cordell R;Wilde MJ;Salman D;Monks PS;Thomas P;Brightling CE;Siddiqui S;Greening NJ
• 通讯作者: Greening NJ